• Aliases: OSI-906, ASP7487
    • An orally bioavailable small molecule that selectively inhibits IGF-1R
    • Phase 3 trial in progress for adrenocortical carcinoma; phase 2 trials in progress for liver, NSCLC, ovarian cancer, and MM
    • Recommended dose: 300 mg PO daily
    • Half-life: 2 to 4 hours
    • Common side effects: Hyperglycemia, nausea/vomiting, elevated lipase
    (Lindsay et al., 2009)
    Other topics in Targeted and Immunotherapy Agents